NEW YORK (GenomeWeb) – Personal Genome Diagnostics and Human Longevity today announced they have signed a collaborative agreement to provide genomic sequencing services to each other.
Human Longevity will have access to PGDx cancer genome analysis panels including CancerSelect, PlasmaSelect, CancerXome, METDetec, and CancerComplete. It has also licensed the PGDx Enterprise Solution platform, which enables laboratories to conduct their own advanced cancer genomic testing using next-generation sequencing.
In turn, Human Longevity will perform whole genome sequencing and analysis for select PGDx customers and for the firm's own research activities.
"Having access to PGDx's capabilities, targeted cancer panels, and Enterprise Solution platform for advanced cancer genomic testing is another important component to our already comprehensive and accurate database of human biological data," Craig Venter, co-founder and CEO of Human Longevity, said in a statement.
PGDx's services characterize genomic alterations in tumors using tissue and liquid biopsies from cancer patients. The firm's targeted gene panels focus on well-characterized genes that have been selected for their high biologic importance in cancer and their relevance to drug targets and pathways.
Financial and other terms of the agreement were not disclosed.